Bolt Biotherapeutics, INC 8-K filings

Bolt Biotherapeutics reported Q2 2026 financial results, highlighting ongoing BDC-4182 Phase 1/2 study progress with initial data expected in Q3 2026, while noting a significant decrease in collaboration revenue and an increase in net loss.

Bolt Biotherapeutics announced the results of its 2026 annual meeting of stockholders, including the election of two Class II directors and the ratification of its independent auditor.

Bolt Biotherapeutics reported Q1 2026 financial results, highlighting ongoing BDC-4182 trials with initial data expected in Q3 2026 and a cash runway into 2027.

Bolt Biotherapeutics announced its fourth quarter and full-year 2025 financial results, highlighting progress in its BDC-4182 clinical trial with initial data expected in Q3 2026 and a cash runway into 2027.

Bolt Biotherapeutics announced its third quarter 2025 financial results and provided a business update, including an expected cash runway into 2027 and initial BDC-4182 clinical data in Q3 2026.

Bolt Biotherapeutics announced a 50% workforce reduction to extend its cash runway into 2027, alongside a delay in initial BDC-4182 clinical data to Q3 2026.

Bolt Biotherapeutics reported significantly reduced operating and net losses in the second quarter of 2025, driven by expense reductions and the advancement of its BDC-4182 cancer immunotherapy into a Phase 1 clinical study.

Bolt Biotherapeutics, Inc. has officially enacted a one-for-twenty reverse stock split of its common stock, effective June 6, 2025, with trading on a split-adjusted basis commencing June 9, 2025.

Bolt Biotherapeutics, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective June 6, 2025, to consolidate shares and potentially maintain Nasdaq listing compliance.

Bolt Biotherapeutics, Inc. announced that its stockholders approved a reverse stock split and elected two Class I directors at its 2025 Annual Meeting held on May 27, 2025.

Bolt Biotherapeutics announced its Q1 2025 financial results, highlighting progress in its immunotherapy pipeline and a cash balance of $58.0 million.

Bolt Biotherapeutics modifies its bylaws to reduce the quorum requirement for stockholder meetings to one-third of outstanding shares.

Bolt Biotherapeutics reports financial results for Q4 and full-year 2024, highlighting progress in clinical trials and a cash runway through mid-2026.

Bolt Biotherapeutics has transferred its stock listing to the Nasdaq Capital Market after failing to meet the minimum bid price requirement, gaining an additional 180 days to regain compliance.

Bolt Biotherapeutics reports the resignation of Dr. Mahendra Shah from its Board of Directors, effective December 31, 2024, and the subsequent appointment of Dr. Jakob Dupont to key committees.

Bolt Biotherapeutics announced its third quarter 2024 financial results and provided a corporate update, highlighting progress in its clinical programs and a cash runway through mid-2026.

Bolt Biotherapeutics has announced the resignation of two board members and the appointment of a new director, effective September 3, 2024.

Bolt Biotherapeutics announced progress in its clinical programs and provided a financial update for the second quarter of 2024, highlighting a cash runway through mid-2026.

Bolt Biotherapeutics has received a notice from Nasdaq that its stock price has fallen below the minimum required for continued listing, triggering a potential delisting process.

Bolt Biotherapeutics held its 2024 annual meeting, electing two directors and ratifying PricewaterhouseCoopers as its independent auditor.

Bolt Biotherapeutics is discontinuing development of trastuzumab imbotolimod, reducing its workforce by 50%, and focusing on new clinical candidates while extending its cash runway into the second half of 2026.

Bolt Biotherapeutics announced its fourth quarter and full-year 2023 financial results, highlighting advancements in its clinical programs and a cash runway through late 2025.